Takeda Gets Second Chance With U.S. FDA Complete Response On Actos Combo Drug
This article was originally published in PharmAsia News
Osaka-based Takeda Pharmaceutical stated this week that it has received a complete response letter from U.S. FDA; the American drug regulator stated in the letter that the NDA review for a fixed-dose alogliptin and Actos (pioglitazone) combo drug will depend on additional data from a cardiovascular safety study FDA requested for the company's alogliptin monotherapy NDA
You may also be interested in...
TOKYO - Takeda Pharmaceutical will make a fresh stab at obtaining U.S. FDA approval for alogliptin, a selective dipeptidyl peptidase IV inhibitor for type 2 diabetes, after receiving a FDA nod for the study design of a cardiovascular outcomes trial, the company said
Pfizer And Astellas Ink Co-promotion Agreement For Hypertension And Cholesterol Combo Drug Caduet In Japan
TOKYO - Pfizer and Astellas Pharma have signed a co-promotion agreement for combination drug, Caduet (amlodipine and atorvastatin) for local Japanese distribution to treat both hypertension and hypercholesterolemia, the first combination drug for the two treatments, the two companies announced Aug. 26
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).